189 related articles for article (PubMed ID: 23298410)
1. Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial.
Lev-Tov H; Li CS; Dahle S; Isseroff RR
Trials; 2013 Jan; 14():8. PubMed ID: 23298410
[TBL] [Abstract][Full Text] [Related]
2. Cellular versus acellular grafts for diabetic foot ulcers: altering the protocol to improve recruitment to a comparative efficacy trial.
Tchanque-Fossuo CN; Dahle SE; Lev-Tov H; Li CS; Isseroff RR
Cutis; 2017 Nov; 100(5):E18-E21. PubMed ID: 29232436
[TBL] [Abstract][Full Text] [Related]
3. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial.
Tchanque-Fossuo CN; Dahle SE; Lev-Tov H; West KIM; Li CS; Rocke DM; Isseroff RR
J Tissue Eng Regen Med; 2019 Aug; 13(8):1430-1437. PubMed ID: 31070860
[TBL] [Abstract][Full Text] [Related]
4. Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study.
Kaur R; Tchanque-Fossuo C; West K; Hadian Y; Gallegos A; Yoon D; Ismailyan L; Schaefer S; Dahle SE; Isseroff RR
Trials; 2020 Jun; 21(1):496. PubMed ID: 32513257
[TBL] [Abstract][Full Text] [Related]
5. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers.
Zelen CM; Orgill DP; Serena T; Galiano R; Carter MJ; DiDomenico LA; Keller J; Kaufman J; Li WW
Int Wound J; 2017 Apr; 14(2):307-315. PubMed ID: 27073000
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of dermal matrix used for diabetic foot ulcer: a systematic review and meta-analysis of randomized controlled trials.
Sui L; Xie Q; Jiang HT; Li XD
BMC Endocr Disord; 2024 Feb; 24(1):23. PubMed ID: 38374102
[TBL] [Abstract][Full Text] [Related]
8. Fetal bovine acellular dermal matrix for the closure of diabetic foot ulcers: a prospective randomised controlled trial.
Lantis JC; Snyder R; Reyzelman AM; Van Gils CC; Sigal F; Vayser D; Caporusso JM; Cazzell S; Lavery LA;
J Wound Care; 2021 Jul; 30(Sup7):S18-S27. PubMed ID: 34256588
[TBL] [Abstract][Full Text] [Related]
9. Human Reticular Acellular Dermal Matrix in the Healing of Chronic Diabetic Foot Ulcerations that Failed Standard Conservative Treatment: A Retrospective Crossover Study.
Zelen CM; Orgill DP; Serena TE; Galiano RD; Carter MJ; DiDomenico LA; Kaufman JP; Keller J; Young NJ; Li WW
Wounds; 2017 Feb; 29(2):39-45. PubMed ID: 28272011
[TBL] [Abstract][Full Text] [Related]
10. Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.
Rastogi A; Kulkarni SA; Agarwal S; Akhtar M; Arsule S; Bhamre S; Bhosle D; Desai S; Deshmukh M; Giriraja KV; Jagannath J; Kashiva RY; Kesavan R; Khandelwal D; Kolte S; Kongara S; Darivemula AK; Madhusudan C; Pyare Saheb Qureshi MAH; Ramu M; Rathod G; Yalamanchi SR; Shakya S; Shetty P; Singh S; Deshpande SK; Viswanathan V; Unnikrishnan AG
JAMA Netw Open; 2023 May; 6(5):e2311509. PubMed ID: 37184839
[TBL] [Abstract][Full Text] [Related]
11. Advances in Dermoepidermal Skin Substitutes for Diabetic Foot Ulcers.
Álvaro-Afonso FJ; García-Álvarez Y; Lázaro-Martínez JL; Kakagia D; Papanas N
Curr Vasc Pharmacol; 2020; 18(2):182-192. PubMed ID: 30963977
[TBL] [Abstract][Full Text] [Related]
12. Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open, randomised controlled clinical trial.
Serena TE; Bullock NM; Cole W; Lantis J; Li L; Moore S; Patel K; Sabo M; Wahab N; Price P
J Wound Care; 2021 May; 30(Sup5):S7-S14. PubMed ID: 33979229
[TBL] [Abstract][Full Text] [Related]
13. Nonpharmacological Management of Diabetic Foot Ulcers: An Update.
Eleftheriadou I; Samakidou G; Tentolouris A; Papanas N; Tentolouris N
Int J Low Extrem Wounds; 2021 Sep; 20(3):188-197. PubMed ID: 33073653
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer.
Snyder RJ; Shimozaki K; Tallis A; Kerzner M; Reyzelman A; Lintzeris D; Bell D; Rutan RL; Rosenblum B
Wounds; 2016 Mar; 28(3):70-7. PubMed ID: 26978860
[TBL] [Abstract][Full Text] [Related]
15. A purified reconstituted bilayer matrix shows improved outcomes in treatment of non-healing diabetic foot ulcers when compared to the standard of care: Final results and analysis of a prospective, randomized, controlled, multi-centre clinical trial.
Armstrong DG; Orgill DP; Galiano RD; Glat PM; Kaufman JP; Carter MJ; DiDomenico LA; Zelen CM
Int Wound J; 2024 Apr; 21(4):e14882. PubMed ID: 38606794
[TBL] [Abstract][Full Text] [Related]
16. Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial.
Hamed S; Ullmann Y; Belokopytov M; Shoufani A; Kabha H; Masri S; Feldbrin Z; Kogan L; Kruchevsky D; Najjar R; Liu PY; Kerihuel JC; Akita S; Teot L
Rejuvenation Res; 2021 Aug; 24(4):251-261. PubMed ID: 33504262
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter, Blinded, Randomized Controlled Clinical Trial Evaluating the Effect of Omega-3-Rich Fish Skin in the Treatment of Chronic, Nonresponsive Diabetic Foot Ulcers.
Lullove EJ; Liden B; Winters C; McEneaney P; Raphael A; Lantis Ii JC
Wounds; 2021 Jul; 33(7):169-177. PubMed ID: 33872197
[TBL] [Abstract][Full Text] [Related]
18. A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study.
Frykberg RG; Franks PJ; Edmonds M; Brantley JN; Téot L; Wild T; Garoufalis MG; Lee AM; Thompson JA; Reach G; Dove CR; Lachgar K; Grotemeyer D; Renton SC;
Diabetes Care; 2020 Mar; 43(3):616-624. PubMed ID: 31619393
[TBL] [Abstract][Full Text] [Related]
19. Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers.
Mutluoglu M; Uzun G; Bennett M; Germonpré P; Smart D; Mathieu D
Diving Hyperb Med; 2016 Sep; 46(3):133-134. PubMed ID: 27723012
[TBL] [Abstract][Full Text] [Related]
20. The LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial.
Game F; Jeffcoate W; Tarnow L; Day F; Fitzsimmons D; Jacobsen J
Trials; 2017 Oct; 18(1):469. PubMed ID: 29017535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
